Humacyte Inc. (HUMA)
NASDAQ: HUMA
· Real-Time Price · USD
1.70
-0.07 (-3.95%)
At close: Oct 16, 2025, 3:59 PM
1.71
0.59%
After-hours: Oct 16, 2025, 07:55 PM EDT
-3.95% (1D)
Bid | 1.67 |
Market Cap | 269.39M |
Revenue (ttm) | 8.05M |
Net Income (ttm) | -58.66M |
EPS (ttm) | -0.47 |
PE Ratio (ttm) | -3.62 |
Forward PE | -5.11 |
Analyst | Buy |
Dividends | n/a |
Ask | 1.76 |
Volume | 4,238,691 |
Avg. Volume (20D) | 5,471,853 |
Open | 1.77 |
Previous Close | 1.77 |
Day's Range | 1.67 - 1.79 |
52-Week Range | 1.15 - 6.77 |
Beta | 1.89 |
Ex-Dividend Date | n/a |
About HUMA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol HUMA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for HUMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsHumacyte Inc. is scheduled to release its earnings on
Nov 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-33.47%
Humacyte shares are trading lower after the compan...
Unlock content with
Pro Subscription
1 week ago
+18.1%
Humacyte shares are trading higher after the company announced the company published long-term results for Ukranian patients treated in real-world combat setting with Symvess in Military Medicine.

2 months ago · seekingalpha.com
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC ProgressI maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles...